IGF::OT::IGF ESTABLISHMENT OF CANCER CELL LINES FOR ADVANCING OVARIAN CANCER HEALTH DISPARITY RESEARCH

卵巢癌（OC）不成比例地影响非裔美国人（AA）背景的妇女在疾病的所有阶段，从介绍到治疗。最令人沮丧的事实是，AA患者的死亡率更高，与白人美国人（CA）相比，他们的生存率不断下降。由于缺乏合适的细胞系模型，在理解和表征现有种族差异中所涉及的机制方面的成功受到很大阻碍。因此，我们的SBIR I期提案的具体目标是标准化开发新型卵巢癌细胞系的程序和协作设置，以推进OC健康差异研究。这将分两部分实现：（A）开发卵巢癌体外细胞系实验模型和AA患者新鲜切除肿瘤/腹水中的成纤维细胞;（B）通过同工酶谱、核型分析、短串联重复序列谱和突变分析对新开发细胞进行遗传表征。此外，我们将对开发的细胞系进行典型形态学、生长速率（群体倍增时间）、致瘤性和转移潜力以及药物敏感性的表征。成功完成拟议的研究将建立一个标准化的方案，用于产生新的OC细胞系模型，从而为我们的下一步，即II期开发多达50个细胞系模型的AA背景的患者以及遗传混合物提供了坚实的基础。

Ovarian cancer (OC) disproportionately affects the women of African American (AA) background at all stages of the disease, from presentation through treatment. Most upsetting fact is that AA patients have greater mortality, and their survival rates are continuously decreasing as compared to Caucasian American (CA). Success in understanding and characterizing the involved mechanisms in existing racial disparity is greatly hampered by the lack of suitable cell line models. Therefore, our specific objective of this SBIR Phase I proposal is to standardize the procedure and collaborative set-up for developing novel ovarian cancer cell lines to advance OC health disparity research. This will be achieved in two parts: (A) development of in vitro cell line experimental model of ovarian cancer and fibroblast cells from freshly-resected tumors/ascites fluid of AA patients; (B) Genetic characterization of newly developed cells by isoenzyme profiling, Karyotyping, short-tandem-repeat profiling and mutational analysis. Moreover, we will characterize the developed cell line for typical morphology, growth rates (population doubling time), tumorigenic and metastatic potential and drug sensitivities. Successful completion of the proposed research would establish a standardized protocol for generation of novel cell line models of OC and thus provide a strong foundation for our next step i.e. Phase II for developing up to 50 cell line models from patients of AA backgrounds as well as genetic admixtures.